Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

AcureX's mission is to halt neurodegenerative diseases starting with Parkinson’s Disease. AcureX expects to have one or more late-preclinical therapeutic candidates for Parkinson’s in human trials in 2023, followed by candidates for other neurodegenerative diseases. AcureX’s approach and founding intellectual property are based on discoveries made by the company’s inventor co-founder, Xinnan Wang MD, Ph.D. Using these...
AcureX's mission is to halt neurodegenerative diseases starting with Parkinson’s Disease. AcureX expects to have one or more late-preclinical therapeutic candidates for Parkinson’s in human trials in 2023, followed by candidates for other neurodegenerative diseases. AcureX’s approach and founding intellectual property are based on discoveries made by the company’s inventor co-founder, Xinnan Wang MD, Ph.D. Using these insights, AcureX has built a Miro1 Mitophagy Discovery Platform to accelerate drug development. AcureX's therapeutics apply to LRRK2-G2019S, SNCA-A53T, and GBA-N370S forms of Parkinson's disease.

List your booth number for exhibitions, ask us